MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Home・Akcijų sąrašas・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

21.63 2.08

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.01

Max

21.69

Pagrindiniai rodikliai
By Trading Economics
Pajamos	7.7M 27M
Pardavimai	20M 265M
P/E Sektoriaus vid.	15.793 35.739
Pelno marža	10.079
Darbuotojai	653
EBITDA	21M 40M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+40.11% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-426M 3.6B
Ankstesnė atidarymo kaina	19.55
Ankstesnė uždarymo kaina	21.63

Naujienos nuotaikos

By Acuity

50%

149 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

14.845 / N/A Palaikymas ir pasipriešinimas

ACADIA Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-02 23:30; UTC

Karštos akcijos

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2025-10-02 21:21; UTC

Uždarbis

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

2025-10-03 00:00; UTC

Įsigijimai, susijungimai, perėmimai

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2025-10-02 23:40; UTC

Rinkos pokalbiai

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2025-10-02 23:39; UTC

Rinkos pokalbiai

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2025-10-02 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2025-10-02 23:00; UTC

Rinkos pokalbiai

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2025-10-02 22:54; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Scales's JV Buyout Lauded by Bull -- Market Talk

2025-10-02 22:54; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-02 22:46; UTC

Rinkos pokalbiai

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2025-10-02 22:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-02 21:17; UTC

Įsigijimai, susijungimai, perėmimai

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2025-10-02 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-10-02 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-02 20:49; UTC

Įsigijimai, susijungimai, perėmimai

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2025-10-02 20:00; UTC

Įsigijimai, susijungimai, perėmimai

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2025-10-02 19:20; UTC

Rinkos pokalbiai

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2025-10-02 19:10; UTC

Rinkos pokalbiai

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2025-10-02 19:04; UTC

Rinkos pokalbiai

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2025-10-02 18:46; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2025-10-02 18:45; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2025-10-02 18:45; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2025-10-02 18:44; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2025-10-02 18:43; UTC

Įsigijimai, susijungimai, perėmimai

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Akcijų palyginimas

Kainos pokytis

ACADIA Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

40.11% į viršų

12 mėnesių prognozė

Vidutinis 29.76 USD 40.11%

Aukščiausias 40 USD

Žemiausias 17 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines ACADIA Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

18 ratings

Pirkti

Laikyti

Parduoti

Remiantis 18 analitikų, pateikusių ACADIA Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.845 / N/APalaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

149 / 371 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.